GSK3A and non-small cell lung carcinoma: Recent studies have demonstrated that the interaction between SHCBP1 and FGF13 could activate the AKT-GSK3α/β signaling pathway and consequently promote the proliferation of the non-small cell lung cancer (NSCLC) cell line A549 [19].